Vertex Pharmaceuticals
VRTX
1,073 hedge funds and large institutions have $60.9B invested in Vertex Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 151 funds opening new positions, 415 increasing their positions, 376 reducing their positions, and 102 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 9 → 24 (+15)
48% more first-time investments, than exits
New positions opened: 151 | Existing positions closed: 102
21% more capital invested
Capital invested by funds: $50.5B → $60.9B (+$10.5B)
10% more repeat investments, than reductions
Existing positions increased: 415 | Existing positions reduced: 376
4% more funds holding
Funds holding: 1,034 → 1,073 (+39)
1.54% more ownership
Funds ownership: 90.66% → 92.2% (+1.5%)
32% less call options, than puts
Call options by funds: $591M | Put options by funds: $867M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$970M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$364M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$272M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$153M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$136M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$451M |
| 2 |
Man Group
London,
United Kingdom
|
-$126M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$120M |
| 4 |
Jennison Associates
New York
|
-$103M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$98.8M |
VRTX Hedge Fund Activity: Q1 2022 in Review
1,073 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2022, worth a combined $60.9B — up 21% from $50.5B a quarter earlier.
Buyers outnumbered sellers: 151 funds opened new VRTX positions and 102 closed out — a net gain of 49 holders — while 415 added to existing stakes and 376 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $970M. The largest seller was Capital International Investors, cutting an estimated $451M.
- 1,073 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2022, up from 1,034 in Q4 2021.
- Funds reported $60.9B of Vertex Pharmaceuticals stock for Q1 2022, up 21% quarter-over-quarter.
- 151 funds opened new Vertex Pharmaceuticals positions in Q1 2022 and 102 closed out, a net change of +49 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2022 was Fidelity Investments, an estimated $970M added.
- The largest Vertex Pharmaceuticals seller in Q1 2022 was Capital International Investors, an estimated $451M sold.
Based on aggregated 13F filings for Q1 2022.